Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 -1.15%91 5-Year Yield-on-Cost % is 6.41 as of Jul. 25, 2026, which is 161% above its 10-year median of 2.46. GuruFocus rates BSP:RADL3 with a GF Score™ of 91/100 and a GF Value™ of R$30.05 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 277 Healthcare Providers & Services companies, Raia Drogasil ranks better than 81.23% on this metric.
Raia Drogasil's yield on cost for the quarter that ended in Mar. 2026 was 6.41.
The historical rank and industry rank for Raia Drogasil's 5-Year Yield-on-Cost % or its related term are showing as below:
BSP:RADL3'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.14 Med: 2.46 Max: 6.78
Current: 6.41
During the past 13 years, Raia Drogasil's highest Yield on Cost was 6.78. The lowest was 1.14. And the median was 2.46.
BSP:RADL3's 5-Year Yield-on-Cost % is ranked better than 81.23% of 277
companies
in the Healthcare Providers & Services industry
Industry Median: 2.9
vs BSP:RADL3: 6.41
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Raia Drogasil 5-Year Yield-on-Cost % Related Terms
For the Pharmaceutical Retailers subindustry, Raia Drogasil's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Raia Drogasil is calculated as
Raia Drogasil (BSP:RADL3) has a 5-Year Yield-on-Cost % of 6.41 as of Jul. 25, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Raia Drogasil and its competitors. This is 161% above median its historical median of 2.46. Over the past decade, Raia Drogasil's 5-Year Yield-on-Cost % has ranged from 1.14 to 6.78. According to the industry distribution chart, Raia Drogasil ranks #52 out of 277 companies in the Healthcare Providers & Services industry, placing it in the top 18.8%.
Is Raia Drogasil's 5-Year Yield-on-Cost % too high?
Raia Drogasil's current 5-Year Yield-on-Cost % of 6.41 is 161% above median its 10-year median of 2.46. Over the past 10 years, this metric has ranged from a low of 1.14 to a high of 6.78. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.90. Raia Drogasil's value of 6.41 is 121% above this industry median. Based on the distribution chart, Raia Drogasil ranks #52 out of 277 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Raia Drogasil has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's 5-Year Yield-on-Cost % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #52 out of 277 companies for 5-Year Yield-on-Cost %. This places Raia Drogasil in the top 19% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.90. Raia Drogasil's value of 6.41 is 121% above this benchmark. Historically, Raia Drogasil's own 5-Year Yield-on-Cost % has ranged from 1.14 to 6.78 over the past decade. While the company's 10-year median is 2.46 vs. the industry median of 2.90, Raia Drogasil has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.90, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current 5-Year Yield-on-Cost % of 6.41 is 121% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current 5-Year Yield-on-Cost % is 6.41, which is 161% above median its own 10-year median of 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$30.05, compared to a current price of R$17.98 — trading 40.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 6.41, which is 161% above median its 10-year median of 2.46 and 121% above the Healthcare Providers & Services industry median of 2.90. Raia Drogasil's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current 5-Year Yield-on-Cost % is 6.41 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$17.98 is trading 40.2% below its estimated GF Value™ of R$30.05.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
5-Year Yield-on-Cost %: 6.41 (161% above median its 10-year median of 2.46)
GF Value™: R$30.05 vs. price of R$17.98 (40.2% below fair value)
Industry Position: 121% above the Healthcare Providers & Services median (#52 of 277)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
91GF Score
Get the complete analysis for BSP:RADL3
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
